alflutinib (ast2818) mesylate (c09-0735-430)

Alflutinib (AST2818) mesylate (C007B-020935)

Catalog No.: C007B-020935
Mfr. No.: A413662-10mg
Mfr. Name: Aladdin Scientific
Qty/UOM: 1
UOM: EA

Price: $421.24

List Price: $468.04

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account. Contact Us

Current Stock:

Quantity:

Adding to cart… The item has been added

Description
Specifications

InformationAlflutinib (AST2818) mesylate is a third-generationepidermal growth factor receptor (EGFR)inhibitor that inhibits both EGFR-sensitive mutations and T790M mutations. Alflutinib (AST2818), primarily metabolized by CYP3A4, is also a potentCYP3A4inducer with EC50 of 0.25 μM.TargetsEGFR ; CYP3A4 (Cell-free assay) ; 0.25 μM(EC50). Specification: 0.98 Molecular Formula: C29H35F3N8O5S Molecular Weight: 664.7 PubChem CID: 134828257 Isomeric SMILES: CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(N=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OCC(F)(F)F.CS(=O)(=O)O Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/A413662-SCI_fcd82a56816d3ec9e275c7871d17e643.pdf

UPC:: 51111726
Condition:: New
Availability:: 2 weeks
Weight:: 0.96 Ounces
HazmatClass:: No
WeightUOM:: LB
MPN:: A413662-10mg
CAS:: 2130958-55-1
Product Size:: 10mg

Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.

"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."